biote (BTMD) Scheduled to Post Earnings on Tuesday

biote (NASDAQ:BTMD - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.05 per share for the quarter. biote has set its FY 2024 guidance at EPS.Investors interested in participating in the company's conference call can do so using this link.

biote (NASDAQ:BTMD - Get Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.06. biote had a negative return on equity of 45.10% and a net margin of 1.79%. The firm had revenue of $45.70 million for the quarter, compared to analyst estimates of $45.50 million. On average, analysts expect biote to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

biote Stock Performance

Shares of BTMD stock traded up $0.03 during trading hours on Tuesday, hitting $5.51. The company had a trading volume of 37,462 shares, compared to its average volume of 105,800. biote has a 12 month low of $3.65 and a 12 month high of $8.22. The firm has a market capitalization of $410.66 million, a price-to-earnings ratio of -25.05 and a beta of 0.87. The firm's fifty day moving average is $5.84 and its 200 day moving average is $5.17.

Analyst Ratings Changes

Several research analysts have recently commented on BTMD shares. Truist Financial reduced their target price on biote from $10.00 to $9.00 and set a "buy" rating on the stock in a report on Thursday, January 18th. Roth Mkm reissued a "buy" rating and issued a $9.00 target price (up from $8.00) on shares of biote in a report on Wednesday, March 13th. B. Riley started coverage on biote in a report on Tuesday, February 20th. They issued a "buy" rating and a $9.00 target price on the stock. Finally, Jefferies Financial Group started coverage on biote in a report on Thursday, February 1st. They issued a "buy" rating and a $6.55 target price on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $8.11.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.